|Type||Buy / Hold / Sell|
|Year End 31st May||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Bioqual, Inc. is engaged in performing contract research services, which is primarily focused on animal models of human diseases, including acquired immune deficiency syndrome (AIDS), influenza, Respiratory Syncytial Virus (RSV) infection, Coronavirus infections (including COVID-19), Flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other emerging infectious diseases. The Company also performs in vitro contract research services. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The In vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. The Company provides its services to the federal government, universities and the life science and pharmaceutical industries.
- 9600 Medical Center Drive, Suite 101, ROCKVILLE, 20850-3336
- +1 2404047654
- Aronson & Co
As of Today at 18:03 UTC, shares in Bioqual are trading at $71.00. This share price information is delayed by 15 minutes.
Shares in Bioqual last closed at $71.00 and the price had moved by -29% over the past 365 days. In terms of relative price strength the Bioqual share price has underperformed the S&P500 Index by -18.92% over the past year.
There is no consensus recommendation for this security.
The Bioqual dividend yield is 1.76% based on the trailing twelve month period.
Last year, Bioqual paid a total dividend of $1.25, and it currently has a trailing dividend yield of 1.76%. We do not have any data on when Bioqual is to next pay dividends.
We do not have data on when Bioqual is to next pay dividends. The historic dividend yield on Bioqual shares is currently 1.76%.
To buy shares in Bioqual you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $71.00, shares in Bioqual had a market capitalisation of $63.50m.
Here are the trading details for Bioqual:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIOQ
Based on an overall assessment of its quality, value and momentum Bioqual is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioqual. Over the past six months, its share price has outperformed the S&P500 Index by +4.48%.
As of the last closing price of $71.00, shares in Bioqual were trading -1.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioqual PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $71.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioqual's management team is headed by:
- Mark Lewis - CHM
- David Newcomer - CFO
- MITCH FRANKLIN - VOP
- Chander Sarma - VPR
- Nancy Madden - VAD
- Hanne Andersen - DRC
- David Landon - DRC